2011) and cancer chemotherapy-induced peripheral neuropathy (CIPN), when administered by chronic and acute dosing regimens, respectively (Trevisan et al. 2013). In other work using EAE rodent models, chronically administered ALA attenuated clinical disease severity (Morini et al. 2004; Wang et al. 2013), but its effect on MS-associated CNP was not investigated. The gene discussed is CNP; the disease is myeloid sarcoma.